TDMS Study 05184-06 Pathology Tables
NTP Experiment-Test: 05184-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GLUTARALDEHYDE Date: 07/13/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:36:10
CORE STUDY
Facility: Battelle Northwest
Chemical CAS #: 111-30-8
Lock Date: 07/01/97
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05184-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GLUTARALDEHYDE Date: 07/13/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:36:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 62.5 PPB 125 PPB 250 PPB
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 11 10 10 12
Natural Death 5 3 4 6
Accidently Killed 1
Survivors
Terminal Sacrifice 34 37 35 32
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (45) (41) (43) (41)
Adenoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Intestine Large, Rectum (47) (47) (48) (45)
Intestine Large, Cecum (47) (47) (47) (46)
Leiomyosarcoma 1 (2%)
Intestine Small, Duodenum (45) (47) (48) (48)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (46) (47) (47) (45)
Carcinoma, Metastatic, Uterus 1 (2%)
Intestine Small, Ileum (46) (48) (47) (46)
Polyp Adenomatous 1 (2%)
Liver (50) (48) (50) (50)
Hemangiosarcoma 2 (4%) 1 (2%) 1 (2%)
Hepatocellular Carcinoma 3 (6%) 6 (13%) 5 (10%) 3 (6%)
Hepatocellular Carcinoma, Multiple 1 (2%) 1 (2%) 1 (2%)
Hepatocellular Adenoma 6 (12%) 11 (23%) 7 (14%) 3 (6%)
Hepatocellular Adenoma, Multiple 5 (10%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Ito Cell Tumor Malignant 1 (2%)
Mesentery (12) (6) (5) (6)
Carcinoma, Metastatic, Uterus 1 (20%)
Histiocytic Sarcoma 1 (20%)
Pancreas (50) (48) (49) (49)
Carcinoma, Metastatic, Uterus 1 (2%)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (50) (49) (50) (50)
Stomach, Forestomach (50) (49) (48) (48)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%) 1 (2%)
NTP Experiment-Test: 05184-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GLUTARALDEHYDE Date: 07/13/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:36:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 62.5 PPB 125 PPB 250 PPB
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Stomach, Glandular (50) (48) (48) (48)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (49) (50) (50)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (49) (49) (50)
Carcinoma, Metastatic, Uterus 1 (2%)
Capsule, Adenoma 1 (2%)
Capsule, Carcinoma 1 (2%) 1 (2%)
Adrenal Medulla (50) (49) (48) (49)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 4 (8%) 1 (2%) 1 (2%) 2 (4%)
Islets, Pancreatic (50) (48) (49) (49)
Adenoma 1 (2%)
Pituitary Gland (49) (49) (49) (50)
Pars Distalis, Adenoma 20 (41%) 16 (33%) 20 (41%) 16 (32%)
Pars Distalis, Carcinoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%) 1 (2%)
Thyroid Gland (50) (48) (50) (50)
Follicular Cell, Adenoma 4 (8%) 2 (4%) 3 (6%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (2)
Carcinoma, Metastatic, Uterus 1 (50%)
Histiocytic Sarcoma 1 (50%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (49) (47) (49) (50)
Carcinoma, Metastatic, Uterus 1 (2%)
Cystadenoma 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Luteoma 2 (4%)
Bilateral, Tubulostromal Adenoma 1 (2%)
Uterus (50) (48) (49) (49)
Adenoma 1 (2%)
Carcinoma 1 (2%) 2 (4%) 2 (4%)
NTP Experiment-Test: 05184-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GLUTARALDEHYDE Date: 07/13/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:36:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 62.5 PPB 125 PPB 250 PPB
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Granular Cell Tumor Benign 1 (2%)
Hemangioma 1 (2%)
Leiomyoma 2 (4%) 1 (2%)
Polyp Stromal 3 (6%) 4 (8%) 3 (6%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (48) (50) (49)
Hemangiosarcoma 1 (2%) 3 (6%) 1 (2%)
Lymph Node (7) (4) (3) (1)
Pancreatic, Histiocytic Sarcoma 1 (14%)
Lymph Node, Bronchial (29) (32) (37) (36)
Histiocytic Sarcoma 1 (3%) 1 (3%)
Lymph Node, Mandibular (43) (40) (39) (38)
Hemangiosarcoma 1 (3%)
Lymph Node, Mesenteric (47) (48) (46) (46)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymph Node, Mediastinal (31) (23) (34) (37)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (4%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (3%)
Histiocytic Sarcoma 1 (3%)
Spleen (50) (48) (48) (49)
Hemangiosarcoma 1 (2%) 3 (6%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Thymus (45) (44) (39) (47)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (49) (49) (50) (49)
Carcinoma 3 (6%) 3 (6%)
Skin (50) (50) (50) (50)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 1 (2%) 3 (6%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Subcutaneous Tissue, Sarcoma 3 (6%)
Subcutaneous Tissue, Sarcoma, Multiple 2 (4%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (49) (50) (50)
Hemangiosarcoma 1 (2%)
Skeletal Muscle (2) (1)
Hemangiosarcoma 1 (100%)
NTP Experiment-Test: 05184-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GLUTARALDEHYDE Date: 07/13/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:36:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 62.5 PPB 125 PPB 250 PPB
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (49) (50) (50)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (49) (50) (48)
Lung (50) (49) (50) (50)
Alveolar/Bronchiolar Adenoma 2 (4%) 3 (6%) 2 (4%) 2 (4%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 4 (8%) 5 (10%) 2 (4%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Carcinoma, Metastatic, Uterus 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 5 (10%) 1 (2%) 2 (4%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Leiomyosarcoma, Metastatic, Intestine Large,
Cecum 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Nose (50) (49) (50) (50)
Pleura (1) (1) (1)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (100%) 1 (100%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (100%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (3) (1) (2)
Adenoma 1 (33%)
Carcinoma 2 (67%) 1 (50%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (49) (49) (49)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Capsule, Sarcoma 1 (2%)
Urinary Bladder (48) (48) (48) (47)
Carcinoma, Metastatic, Uterus 1 (2%)
Histiocytic Sarcoma 1 (2%)
NTP Experiment-Test: 05184-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GLUTARALDEHYDE Date: 07/13/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:36:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 62.5 PPB 125 PPB 250 PPB
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Lymphoma Malignant 12 (24%) 12 (24%) 8 (16%) 12 (24%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05184-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GLUTARALDEHYDE Date: 07/13/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:36:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 62.5 PPB 125 PPB 250 PPB
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 41 44 41 40
Total Primary Neoplasms 81 81 77 62
Total Animals with Benign Neoplasms 32 32 30 26
Total Benign Neoplasms 50 42 42 32
Total Animals with Malignant Neoplasms 24 26 24 25
Total Malignant Neoplasms 31 39 35 30
Total Animals with Metastatic Neoplasms 3 6 4 3
Total Metastatic Neoplasm 7 8 13 3
Total Animals with Malignant Neoplasms 1 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
NTP Experiment-Test: 05184-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GLUTARALDEHYDE Date: 07/13/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:36:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 62.5 PPB 125 PPB 250 PPB
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 13 15 6 5
Natural Death 6 8 4 7
Survivors
Terminal Sacrifice 31 27 40 38
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (42) (36) (41) (46)
Sarcoma, Metastatic, Mesentery 1 (2%)
Intestine Large, Cecum (45) (44) (48) (47)
Intestine Small, Duodenum (43) (43) (47) (46)
Carcinoma 1 (2%)
Intestine Small, Jejunum (43) (44) (47) (46)
Intestine Small, Ileum (44) (46) (48) (47)
Liver (49) (50) (50) (49)
Hemangiosarcoma 2 (4%) 3 (6%) 2 (4%)
Hepatocellular Carcinoma 15 (31%) 9 (18%) 10 (20%) 10 (20%)
Hepatocellular Carcinoma, Multiple 6 (12%) 2 (4%) 2 (4%)
Hepatocellular Adenoma 15 (31%) 7 (14%) 16 (32%) 9 (18%)
Hepatocellular Adenoma, Multiple 4 (8%) 3 (6%) 4 (8%) 2 (4%)
Hepatocholangiocarcinoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 3 (6%)
Mesentery (2) (2) (3) (5)
Sarcoma 1 (33%)
Pancreas (47) (49) (50) (48)
Sarcoma, Metastatic, Mesentery 1 (2%)
Stomach, Forestomach (48) (49) (50) (48)
Sarcoma, Metastatic, Mesentery 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (46) (47) (50) (48)
Tooth (13) (17) (10) (19)
Odontoma 1 (8%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 05184-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GLUTARALDEHYDE Date: 07/13/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:36:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 62.5 PPB 125 PPB 250 PPB
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (49) (50) (50) (49)
Hemangiosarcoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (47) (49) (50) (49)
Capsule, Adenoma 2 (4%) 3 (6%) 1 (2%)
Pituitary Gland (46) (47) (48) (47)
Pars Distalis, Adenoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (48) (49) (49) (49)
Bilateral, Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Adenoma 3 (6%) 2 (4%) 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (48) (50) (50) (49)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Preputial Gland (48) (49) (50) (47)
Squamous Cell Carcinoma 1 (2%)
Prostate (49) (48) (50) (47)
Seminal Vesicle (47) (49) (50) (49)
Granular Cell Tumor Benign 1 (2%)
Testes (48) (50) (50) (50)
Interstitial Cell, Adenoma 1 (2%) 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (48) (47) (50) (49)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Lymph Node (1) (2) (1) (1)
Lymph Node, Bronchial (34) (28) (35) (37)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%)
NTP Experiment-Test: 05184-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GLUTARALDEHYDE Date: 07/13/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:36:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 62.5 PPB 125 PPB 250 PPB
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Histiocytic Sarcoma 1 (3%)
Lymph Node, Mandibular (36) (22) (30) (33)
Lymph Node, Mesenteric (46) (44) (47) (47)
Sarcoma, Metastatic, Mesentery 1 (2%)
Lymph Node, Mediastinal (29) (27) (33) (30)
Histiocytic Sarcoma 1 (3%)
Spleen (48) (48) (50) (48)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Thymus (39) (34) (43) (44)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (48) (50) (50) (48)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (48) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 8 (17%) 10 (20%) 9 (18%) 6 (12%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 9 (19%) 6 (12%) 7 (14%) 6 (12%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 6 (13%) 2 (4%) 6 (12%) 4 (8%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 2 (4%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Pleura (1) (2)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (100%) 1 (50%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 05184-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GLUTARALDEHYDE Date: 07/13/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:36:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 62.5 PPB 125 PPB 250 PPB
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (4) (5) (2) (2)
Adenoma 3 (75%) 3 (60%) 2 (100%) 1 (50%)
Carcinoma 1 (25%) 2 (40%) 1 (50%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (48) (49) (50) (49)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant, Metastatic, Bone
Marrow 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 3 (6%) 1 (2%)
Lymphoma Malignant 4 (8%) 5 (10%) 1 (2%) 5 (10%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 05184-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC GLUTARALDEHYDE Date: 07/13/98
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:36:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 62.5 PPB 125 PPB 250 PPB
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 44 42 39 33
Total Primary Neoplasms 75 64 66 54
Total Animals with Benign Neoplasms 27 24 29 19
Total Benign Neoplasms 36 28 39 23
Total Animals with Malignant Neoplasms 33 28 23 22
Total Malignant Neoplasms 39 36 27 31
Total Animals with Metastatic Neoplasms 6 4 8 5
Total Metastatic Neoplasm 6 7 14 6
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------